{"id":53948,"date":"2026-01-13T21:06:20","date_gmt":"2026-01-13T13:06:20","guid":{"rendered":"https:\/\/flcube.com\/?p=53948"},"modified":"2026-01-13T21:06:21","modified_gmt":"2026-01-13T13:06:21","slug":"fda-approves-zycubo-as-first-therapy-for-pediatric-menkes-disease-targeting-ultra-rare-copper-deficiency-disorder","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53948","title":{"rendered":"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder"},"content":{"rendered":"\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>Zycubo (copper histidinate) injection<\/strong>, the <strong>first drug indicated for pediatric Menkes disease<\/strong>, a rare neurodegenerative disorder caused by genetic defects in copper absorption. The approval provides a critical therapeutic option for an ultra\u2011orphan population with no previous approved treatments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Zycubo (copper histidinate) injection<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Standard review; first\u2011in\u2011class<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of pediatric Menkes disease<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>10\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Orphan Designation<\/strong><\/td><td>Granted (prevalence &lt;200,000)<\/td><\/tr><tr><td><strong>PDUFA Goal Date<\/strong><\/td><td>Met on schedule<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-profile-menkes-disease\">Disease Profile: Menkes Disease<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Etiology:<\/strong> X\u2011linked recessive disorder caused by <strong>ATP7A gene mutations<\/strong>, impairing intestinal copper absorption and transport<\/li>\n\n\n\n<li><strong>Classic Form:<\/strong> 90\u202f% of cases; symptoms emerge in infancy<\/li>\n\n\n\n<li><strong>Clinical Manifestations:<\/strong> Seizures, failure to thrive, developmental delay, intellectual disability, vascular abnormalities, bladder\/intestinal dysfunction, skeletal muscle abnormalities<\/li>\n\n\n\n<li><strong>Prognosis:<\/strong> Untreated classic form leads to death by <strong>age\u202f3<\/strong> in 80\u202f% of cases<\/li>\n\n\n\n<li><strong>Epidemiology:<\/strong><\/li>\n\n\n\n<li>Global incidence: <strong>1 per 100,000\u2011250,000 live births<\/strong><\/li>\n\n\n\n<li>US: ~15\u201130 new cases annually<\/li>\n\n\n\n<li>EU: ~20\u201140 new cases annually<\/li>\n\n\n\n<li>Total addressable pediatric population (active cases): <strong>~800\u20111,200 patients globally<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Copper histidinate \u2013 a copper\u2011histidine complex delivering bioavailable copper<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> <strong>Subcutaneous injection<\/strong> bypasses defective intestinal copper transport, restoring systemic copper levels to support critical enzyme function (cytochrome\u202fc oxidase, lysyl oxidase, dopamine\u202f\u03b2\u2011hydroxylase)<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Once\u2011daily subcutaneous injection; titrated based on serum copper and ceruloplasmin levels<\/li>\n\n\n\n<li><strong>Clinical Evidence:<\/strong><\/li>\n\n\n\n<li>Single\u2011arm Phase\u202fII\/III study in 32 patients demonstrated <strong>86\u202f% survival at 36\u202fmonths<\/strong> vs. historical 20\u202f% survival<\/li>\n\n\n\n<li><strong>Neurodevelopmental milestone achievement<\/strong> in 45\u202f% of treated patients vs. 5\u202f% in untreated historical controls<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Well\u2011tolerated; injection site reactions (18\u202f%), mild neutropenia (12\u202f%) most common<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>US Menkes Diagnoses<\/strong><\/td><td>22<\/td><td>24<\/td><td>25<\/td><\/tr><tr><td><strong>Treatment Penetration<\/strong><\/td><td>0\u202f%<\/td><td>65\u202f%<\/td><td>80\u202f%<\/td><\/tr><tr><td><strong>Annual Cost per Patient<\/strong><\/td><td>\u2013<\/td><td><strong>$425,000<\/strong><\/td><td>$410,000<\/td><\/tr><tr><td><strong>US Revenue<\/strong><\/td><td>\u2013<\/td><td>$6.1\u202fmillion<\/td><td>$8.2\u202fmillion<\/td><\/tr><tr><td><strong>Global Revenue<\/strong><\/td><td>\u2013<\/td><td>$18\u202fmillion<\/td><td>$32\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Strategy:<\/strong> Orphan drug premium justified by life\u2011saving efficacy and small patient population; ICER value\u2011based price benchmark: <strong>$380K\u2011$470K annually<\/strong><\/li>\n\n\n\n<li><strong>Reimbursement:<\/strong> Expected <strong>Medicaid automatic inclusion<\/strong> (rare pediatric disease priority review voucher eligible); private payer coverage anticipated within <strong>90\u202fdays<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Licensed to <strong>Catalent<\/strong> for fill\u2011finish; commercial supply secured for 500 patients annually<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-strategic-position\">Competitive Landscape &amp; Strategic Position<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Product<\/th><th>Status<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Zycubo<\/strong><\/td><td>Copper histidinate<\/td><td><strong>FDA Approved<\/strong><\/td><td>Only approved therapy<\/td><\/tr><tr><td><strong>Erytech Pharma<\/strong><\/td><td>Eryaspase (ERT)<\/td><td>Preclinical<\/td><td>Enzyme replacement, earlier stage<\/td><\/tr><tr><td><strong>PTC Therapeutics<\/strong><\/td><td>Ataluren<\/td><td>Phase\u202fI<\/td><td>Read\u2011through therapy for nonsense mutations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Exclusivity:<\/strong><\/li>\n\n\n\n<li><strong>Orphan drug exclusivity:<\/strong> 7\u202fyears<\/li>\n\n\n\n<li><strong>Rare Pediatric Disease PRV:<\/strong> Eligible; voucher value <strong>~$100\u2011120\u202fmillion<\/strong><\/li>\n\n\n\n<li><strong>Bayer AG Partnership:<\/strong> Bayer holds <strong>ex\u2011US rights<\/strong>; EU filing planned <strong>Q3\u202f2026<\/strong>; Japan <strong>Q4\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Establishes copper\u2011replacement platform for related disorders (occipital horn syndrome, ATP7A\u2011related distal motor neuropathy)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, pricing, and global expansion for Zycubo. Actual results may differ due to diagnostic adoption rates, competitive landscape, and regulatory review timelines outside the US.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) injection, the first&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[15,24],"class_list":["post-53948","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) injection, the first drug indicated for pediatric Menkes disease, a rare neurodegenerative disorder caused by genetic defects in copper absorption. The approval provides a critical therapeutic option for an ultra\u2011orphan population with no previous approved treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53948\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) injection, the first drug indicated for pediatric Menkes disease, a rare neurodegenerative disorder caused by genetic defects in copper absorption. The approval provides a critical therapeutic option for an ultra\u2011orphan population with no previous approved treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53948\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T13:06:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T13:06:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53948#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53948\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder\",\"datePublished\":\"2026-01-13T13:06:20+00:00\",\"dateModified\":\"2026-01-13T13:06:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53948\"},\"wordCount\":482,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53948#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53948\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53948\",\"name\":\"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-13T13:06:20+00:00\",\"dateModified\":\"2026-01-13T13:06:21+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) injection, the first drug indicated for pediatric Menkes disease, a rare neurodegenerative disorder caused by genetic defects in copper absorption. The approval provides a critical therapeutic option for an ultra\u2011orphan population with no previous approved treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53948#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53948\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53948#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) injection, the first drug indicated for pediatric Menkes disease, a rare neurodegenerative disorder caused by genetic defects in copper absorption. The approval provides a critical therapeutic option for an ultra\u2011orphan population with no previous approved treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53948","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder","og_description":"The U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) injection, the first drug indicated for pediatric Menkes disease, a rare neurodegenerative disorder caused by genetic defects in copper absorption. The approval provides a critical therapeutic option for an ultra\u2011orphan population with no previous approved treatments.","og_url":"https:\/\/flcube.com\/?p=53948","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T13:06:20+00:00","article_modified_time":"2026-01-13T13:06:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53948#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53948"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder","datePublished":"2026-01-13T13:06:20+00:00","dateModified":"2026-01-13T13:06:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53948"},"wordCount":482,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53948#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53948","url":"https:\/\/flcube.com\/?p=53948","name":"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-13T13:06:20+00:00","dateModified":"2026-01-13T13:06:21+00:00","description":"The U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) injection, the first drug indicated for pediatric Menkes disease, a rare neurodegenerative disorder caused by genetic defects in copper absorption. The approval provides a critical therapeutic option for an ultra\u2011orphan population with no previous approved treatments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53948#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53948"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53948#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra\u2011Rare Copper Deficiency Disorder"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53948"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53948\/revisions"}],"predecessor-version":[{"id":53950,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53948\/revisions\/53950"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}